Methyldigoxin

794.969

794.97

250-292-0

I7GG1YUC5V

DTXSID0023294

C01AA08|C - Cardiovascular system

192

2.87220

1.33g/cm3

200-202°C (dec.)

914.1ºC at 760mmHg

270.5ºC

1.589

Hygroscopic, Refrigerator, Under Inert Atmosphere

LD50 in rats, mice (mg/kg): 4.8, 4.9 i.v.; 6.2, 4.8 i.p.; 8.3, 7.8 orally (Czerwek)

P260, P261, P264, P270, P271, P273, P280, P284, P301+P310, P304+P340, P305+P351+P338, P310, P311, P314, P320, P321, P330, P337+P313, P391, P403+P233, P405, P501

H300

|Danger|H300 (100%): Fatal if swallowed [Danger Acute toxicity, oral]|P260, P261, P264, P270, P271, P273, P280, P284, P301+P310, P304+P340, P305+P351+P338, P310, P311, P314, P320, P321, P330, P337+P313, P391, P403+P233, P405, and P501|Aggregated GHS information provided by 2 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)|Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)|Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)

4''' O Methyldigoxin